{"resourceType":"Task","id":"PGxRecEx01","meta":{"profile":["http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/followup-recommendation"]},"text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative</b></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource \"PGxRecEx01\" </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-followup-recommendation.html\">Followup Recommendation</a></p></div><p><b>status</b>: requested</p><p><b>intent</b>: proposal</p><p><b>code</b>: Consider alternative medication <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://loinc.org/\">LOINC</a>#LA26421-0)</span></p><p><b>description</b>: For clopidogrel, individuals with this diplotype are expected to have significantly reduced platelet inhibition, increased residual platelet aggregation and increased risk for adverse cardiovascular events in response to clopidogrel. Alternative antiplatelet therapy (if no contraindication) is recommended. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline- for-clopidogrel-and-cyp2c19/</p><p><b>for</b>: <a href=\"Patient-CGPatientExample01.html\">Patient/CGPatientExample01</a> \" EVERYMAN\"</p><p><b>reasonReference</b>: <a href=\"Observation-TxImp01.html\">Observation/TxImp01: Poor metabolizer</a></p></div>"},"status":"requested","intent":"proposal","code":{"coding":[{"system":"http://loinc.org","code":"LA26421-0","display":"Consider alternative medication"}]},"description":"For clopidogrel, individuals with this diplotype are expected to have significantly reduced platelet inhibition, increased residual platelet aggregation and increased risk for adverse cardiovascular events in response to clopidogrel. Alternative antiplatelet therapy (if no contraindication) is recommended. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline- for-clopidogrel-and-cyp2c19/","for":{"reference":"Patient/CGPatientExample01"},"reasonReference":{"reference":"Observation/TxImp01","display":"Poor metabolizer"}}